FDA 483 - IVF Institute, P.A. - March 04, 2019

An FDA inspection of IVF Institute, P.A. in Dallas, TX, revealed significant deficiencies in their HCT/P reproductive services. The firm failed to establish and document adequate procedures for screening and determining donor eligibility. Furthermore, donors were determined eligible without complete screening and testing results, specifically regarding communicable disease agents.